XTRA:AFXMedical Equipment
Carl Zeiss Meditec (XTRA:AFX) Could Be 6% Overvalued As 2026 Guidance Lands
Carl Zeiss Meditec (XTRA:AFX) is in focus after issuing 2026 revenue guidance of about €2.15b to €2.20b, alongside planned goodwill impairment of roughly €150 million in its Ophthalmology segment for the fourth quarter.
See our latest analysis for Carl Zeiss Meditec.
The updated 2026 revenue outlook and planned €150 million goodwill impairment land at a time when Carl Zeiss Meditec’s share price has risen 22.35% over 90 days. However, the 1 year total shareholder return is still down 29.17%,...